{"id":14663,"date":"2022-12-23T09:00:00","date_gmt":"2022-12-23T09:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3972845_CN72845_0"},"modified":"2022-12-23T09:00:00","modified_gmt":"2022-12-23T09:00:00","slug":"hyphens-pharma-licenses-winlevi-for-all-10-asean-countries-from-cosmo-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=14663","title":{"rendered":"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals"},"content":{"rendered":"<ul type=\"disc\">\n<li><b>Winlevi\u00ae is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in <span class=\"xn-chron\">August 2020<\/span>.<\/b><\/li>\n<li><b>It will reinforce our Proprietary Brand segment&#8217;s dermatological franchise. <\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 23, 2022<\/span><\/span> \/PRNewswire\/ &#8212; Hyphens Pharma International Limited (&#8220;<b>Hyphens Pharma<\/b>&#8220;, or the &#8220;<b>Company<\/b>&#8220;, and together with its subsidiaries, the &#8220;<b>Group<\/b>&#8220;), <span class=\"xn-location\">Singapore&#8217;s<\/span> leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into exclusive license and supply agreements with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (&#8220;<b>Cosmo<\/b>&#8220;) for the exclusive rights to develop and commercialize Winlevi\u00ae (clascoterone) cream 1% and all future product extension and\/or improvement in the treatment of acne in 10 countries across <span class=\"xn-location\">Southeast Asia<\/span>.<\/p>\n<p>Winlevi\u00ae (<a href=\"http:\/\/www.winlevi.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.winlevi.com<\/a>) is a U.S. Food &amp; Drug Administration (&#8220;<b>FDA<\/b>&#8220;) approved novel drug with a unique mechanism of action for the topical treatment of acne in patients aged 12 years and older. It is the first-in-class topical androgen receptor inhibitor that tackles the androgen hormone component of acne and is the first new type of acne medication approved by the FDA since 1982. As the only topical cream to treat hormonal acne directly in the skin, it offers a non-antibiotic approach for acne-sufferers everywhere. Winlevi\u00ae inhibits sebum production and inflammation by targeting the androgen receptors in the sebaceous gland cells. Oral treatments are typically prescribed to address hormonal acne, but usually only prescribed to females. With Winlevi\u00ae, males suffering from acne, as well as females who don&#8217;t want to take oral medications, can now benefit from this first-in-class treatment, making Winlevi\u00ae a game-changer in the fight against acne.<\/p>\n<p>Launched in the U.S. in <span class=\"xn-chron\">November 2021<\/span>, Winlevi\u00ae is already the most prescribed branded topical acne drug in the U.S. based on IQVIA data. Over 12,000 U.S. physicians have prescribed Winlevi\u00ae to date. According to the prescriptions generated, Winlevi\u00ae has been one of the most successful U.S. launches in the topical acne space in the last 15 years.&nbsp;<\/p>\n<p>In a study involving 3,888 Singapore Chinese subjects, the estimated prevalence of acne vulgaris is 53.8%<sup>[1]<\/sup>. Acne can have profound social and psychological effects on adolescents or young adults when it affects their self-esteem<sup>[2]<\/sup>. As the first novel acne drug in decades, Winlevi\u00ae has huge potential to revolutionize the acne treatment space. Winlevi\u00ae will be Hyphens Pharma&#8217;s first innovative therapeutics, deepening its dermatology pipeline.<\/p>\n<p>Today, Hyphens Pharma has a proprietary range of dermatological products for acne, atopic dermatitis, hyperpigmentation, and hair loss. These are available through doctors including dermatologists, paediatricians, and general practitioners as well as major retail pharmacies.<\/p>\n<p><b><span class=\"xn-person\">Diana Harbort<\/span>, President of Cosmo&#8217;s Dermatology Division,<\/b>&nbsp;said: <i>&#8220;We are very pleased to partner with Hyphens Pharma. Their strong expertise in <span class=\"xn-location\">Southeast Asia<\/span> gives us great confidence in their ability to gain regulatory approval and commercialise Winlevi\u00ae in the region. The success of Winlevi\u00ae in the U.S. has given us the opportunity to select the best partners in each region and to eventually make the product available to more patients around the globe.&#8221;<\/i><\/p>\n<p><b><span class=\"xn-person\">Lim See Wah<\/span>, Executive Chairman and CEO of Hyphens Pharma<\/b>, said: <i>&#8220;Acne is a medical condition that affects millions in the ASEAN region. Yet, the medical management of acne remained largely similar due to the absence of new drugs.&nbsp; Winlevi\u00ae is the first new class of topical drug for the treatment of acne that is approved by U.S. FDA in nearly 40 years. We are thus very proud to be able to bring Winlevi\u00ae to doctors and patients in the entire ASEAN region. We would like to thank Cosmo for this partnership and their confidence in Hyphens Pharma. This deal also affirms Hyphens Pharma&#8217;s strength as ASEAN&#8217;s leading specialty pharmaceutical company with a strong focus on skin health.&nbsp; We will continue to innovate, as well as to bring to market relevant innovations from the world to our region, so as to continue serving our doctors and patients.&#8221; <\/i><\/p>\n<p><b>About Hyphens Pharma International Limited (<a href=\"http:\/\/www.hyphensgroup.com\/\" target=\"_blank\" rel=\"nofollow noopener\">http:\/\/www.hyphensgroup.com<\/a>)&nbsp; <\/b><\/p>\n<p>Hyphens Pharma International Limited and its subsidiaries (the &#8220;Group&#8221;) is <span class=\"xn-location\">Singapore&#8217;s<\/span> leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in <span class=\"xn-location\">Singapore<\/span>, <span class=\"xn-location\">Vietnam<\/span>, <span class=\"xn-location\">Malaysia<\/span>, <span class=\"xn-location\">Indonesia<\/span> and <span class=\"xn-location\">the Philippines<\/span>, and is supplemented by a marketing and distribution network covering 10 other markets \u2013 <span class=\"xn-location\">Bangladesh<\/span>, <span class=\"xn-location\">Brunei<\/span>, <span class=\"xn-location\">Cambodia<\/span>, <span class=\"xn-location\">China<\/span>, Hong Kong S.A.R., Macau S.A.R., <span class=\"xn-location\">Myanmar<\/span>, <span class=\"xn-location\">Oman<\/span>, <span class=\"xn-location\">South Korea<\/span> and <span class=\"xn-location\">Sri Lanka<\/span>.<\/p>\n<p><span class=\"xn-location\">Singapore<\/span> is the Group&#8217;s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group&#8217;s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart &amp; Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">the United States<\/span>, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients&#8217; homes.<\/p>\n<p><b>About Cosmo N.V. (<a href=\"https:\/\/www.cosmopharma.com\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.cosmopharma.com<\/a>)<\/b><\/p>\n<p>Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda\u00ae\/Mezavant\u00ae\/Mesavancol\u00ae, Uceris\u00ae\/Cortiment\u00ae, Aemcolo\u00ae\/ Relafalk\u00ae and Winlevi\u00ae. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius\u2122 which uses artificial intelligence to help detect potential signs of colon cancer. The company also has a rich development pipeline.<\/p>\n<div>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" class=\"prnbcc\">\n<tbody readability=\"4.12109375\">\n<tr readability=\"3\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Issued on behalf of<\/span><\/p>\n<\/td>\n<td class=\"prnpr2 prnpl2 prncbts prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Hyphens Pharma International Limited<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"6\">\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">For media enquires contact<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">:<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\" readability=\"5\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Mr Derek Chng \/ Mr Gerald Woon<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"2.0853658536585\">\n<td class=\"prnpr2 prnpl2 prntal prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Email \/ DID \/ Mobile<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\"><span class=\"prnews_span\">:<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\" readability=\"2.8813559322034\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><a href=\"mailto:derekchng@cogentcomms.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow noopener\">derekchng@cogentcomms.com<\/a><\/span><span class=\"prnews_span\"> \/ <\/span><span class=\"prnews_span\">(65) 6704 9285 \/ (65) 9638 8635<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"1.8888888888889\">\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\"><\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\"><\/td>\n<td class=\"prngen6\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\" readability=\"3.1481481481481\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><u><a href=\"mailto:woon@cogentcomms.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow noopener\">woon@cogentcomms.com<\/a><\/u> \/ (65) 6704 9268 \/ (65) 9694 8364<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><i>This media release has been reviewed by the Company&#8217;s sponsor, SAC Capital Private Limited (the &#8220;Sponsor&#8221;). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the &#8220;SGX-ST&#8221;) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release. <\/i><\/p>\n<p><i>The contact person for the Sponsor is Ms <span class=\"xn-person\">Lee Khai Yinn<\/span> (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, <span class=\"xn-location\">Singapore<\/span> 048542.<\/i><\/p>\n<div>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\" class=\"prnbcc\">\n<tbody readability=\"4.5\">\n<tr readability=\"9\">\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\" readability=\"9\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><sup>[1]&nbsp;<\/sup>Heng&nbsp;AHS&nbsp;et&nbsp;al. Epidemiological Risk Factors Associated with Acne&nbsp;Vulgaris&nbsp;Presentation, Severity, and Scarring in a Singapore Chinese Population: A Cross-Sectional Study. Dermatology. 2022;238(2):226-235.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4.5\">\n<td class=\"prngen7\" colspan=\"1\" rowspan=\"1\" readability=\"6\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><sup>[2]<\/sup>&nbsp;Moosa&nbsp;AS&nbsp;et&nbsp;al. Primary care approach to managing acne. Singapore&nbsp;Med&nbsp;J. 2021 Nov;62(11):568-573.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23\"> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/hyphens-pharma-licenses-winlevi-for-all-10-asean-countries-from-cosmo-pharmaceuticals-301709489.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/hyphens-pharma-licenses-winlevi-for-all-10-asean-countries-from-cosmo-pharmaceuticals-301709489.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Winlevi\u00ae is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020. It will reinforce our Proprietary Brand segment&#8217;s dermatological franchise. SINGAPORE, Dec. 23, 2022 \/PRNewswire\/ &#8212; Hyphens Pharma International Limited (&#8220;Hyphens Pharma&#8220;, or the &#8220;Company&#8220;, and together with its subsidiaries, the &#8220;Group&#8220;), Singapore&#8217;s leading specialty pharmaceutical and consumer [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-14663","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=14663\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals - My Blog\" \/>\n<meta property=\"og:description\" content=\"Winlevi\u00ae is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020. It will reinforce our Proprietary Brand segment&#8217;s dermatological franchise. SINGAPORE, Dec. 23, 2022 \/PRNewswire\/ &#8212; Hyphens Pharma International Limited (&#8220;Hyphens Pharma&#8220;, or the &#8220;Company&#8220;, and together with its subsidiaries, the &#8220;Group&#8220;), Singapore&#8217;s leading specialty pharmaceutical and consumer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=14663\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-23T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals\",\"datePublished\":\"2022-12-23T09:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663\"},\"wordCount\":1154,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN72845&amp;sd=2022-12-23\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663\",\"name\":\"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN72845&amp;sd=2022-12-23\",\"datePublished\":\"2022-12-23T09:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN72845&amp;sd=2022-12-23\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CN72845&amp;sd=2022-12-23\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=14663#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=14663","og_locale":"en_US","og_type":"article","og_title":"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals - My Blog","og_description":"Winlevi\u00ae is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020. It will reinforce our Proprietary Brand segment&#8217;s dermatological franchise. SINGAPORE, Dec. 23, 2022 \/PRNewswire\/ &#8212; Hyphens Pharma International Limited (&#8220;Hyphens Pharma&#8220;, or the &#8220;Company&#8220;, and together with its subsidiaries, the &#8220;Group&#8220;), Singapore&#8217;s leading specialty pharmaceutical and consumer [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=14663","og_site_name":"My Blog","article_published_time":"2022-12-23T09:00:00+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=14663#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=14663"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals","datePublished":"2022-12-23T09:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=14663"},"wordCount":1154,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=14663#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=14663","url":"https:\/\/transmediavictoria.net.au\/?p=14663","name":"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=14663#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=14663#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23","datePublished":"2022-12-23T09:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=14663#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=14663"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=14663#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN72845&amp;sd=2022-12-23"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=14663#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Hyphens Pharma licenses Winlevi\u00ae for all 10 ASEAN countries from Cosmo Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/14663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14663"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/14663\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}